• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨矿物质标志物达标与轻度升高全段甲状旁腺素水平血液透析患者生存的人群水平关联:病例-队列研究。

Population-level associations of achievement of targets for bone-mineral markers with survival in haemodialysis patients with mildly elevated intact-PTH levels: a case-cohort study.

机构信息

Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Department of Healthcare Epidemiology, School of Public Health, Kyoto University Graduate School of Medicine, Kyoto, Japan.

出版信息

Sci Rep. 2019 Aug 5;9(1):11301. doi: 10.1038/s41598-019-47852-8.

DOI:10.1038/s41598-019-47852-8
PMID:31383933
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6683189/
Abstract

Achieving calcium, phosphorus, and intact parathyroid hormone (PTH) targets helps improve dialysis population outcomes. We aimed to assess the population-level associations of achievement of those targets with survival using population-attributable-fractions (PAFs). We conducted a case-cohort study using data from 8229 haemodialysis patients with mildly elevated intact PTH, treated at 86 dialysis facilities in Japan. We examined associations among calcium, phosphorus, intact PTH, and mortality over 3 years. We estimated PAFs for achieving the targets of calcium, phosphorus, and intact PTH from the adjusted hazard ratios by Cox regression models. Proportions within the recommended range were 55.8%, 63.3%, and 39.1% for calcium (8.4-10.0 mg/dL), phosphorus (3.5-6.0 mg/dL) and intact PTH (60-240 pg/mL), respectively. The mortality rate was 5.7 per 100 person-years. Mortality was independently associated with non-achievement of targets. Regarding the population-level impact, statistically significant PAFs were found for achieving the combination of calcium and phosphorus (8.8%; 95% CI, 1.1-16.0). Further, PAF for combined calcium, phosphorus, and intact PTH was the largest (16.8%; 95% CI, 5.6-30.4). In conclusion, there might be additive and substantial population-level associations between survival and the achievement of calcium, phosphorus, and intact-PTH targets in the haemodialysis population with mildly elevated intact PTH.

摘要

实现钙、磷和全段甲状旁腺激素 (PTH) 的目标有助于改善透析人群的预后。我们旨在使用人群归因分数 (PAF) 评估实现这些目标与生存率之间的人群相关性。我们使用日本 86 个透析中心的 8229 名轻度升高的全段 PTH 血液透析患者的数据进行了病例对照研究。我们研究了钙、磷、全段 PTH 与 3 年内死亡率之间的相关性。我们通过 Cox 回归模型中的调整后的危险比来估计实现钙、磷和全段 PTH 目标的 PAF。钙 (8.4-10.0mg/dL)、磷 (3.5-6.0mg/dL) 和全段 PTH (60-240pg/mL) 推荐范围内的比例分别为 55.8%、63.3%和 39.1%。死亡率为每 100 人年 5.7 人。死亡率与未达到目标独立相关。就人群水平的影响而言,钙和磷联合达标具有统计学意义的 PAF(8.8%;95%CI,1.1-16.0)。此外,钙、磷和全段 PTH 联合达标 PAF 最大(16.8%;95%CI,5.6-30.4)。总之,在轻度升高的全段 PTH 的血液透析人群中,生存与钙、磷和全段 PTH 目标的实现之间可能存在相加且显著的人群相关性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5cd7/6683189/b190090803c3/41598_2019_47852_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5cd7/6683189/b190090803c3/41598_2019_47852_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5cd7/6683189/b190090803c3/41598_2019_47852_Fig1_HTML.jpg

相似文献

1
Population-level associations of achievement of targets for bone-mineral markers with survival in haemodialysis patients with mildly elevated intact-PTH levels: a case-cohort study.骨矿物质标志物达标与轻度升高全段甲状旁腺素水平血液透析患者生存的人群水平关联:病例-队列研究。
Sci Rep. 2019 Aug 5;9(1):11301. doi: 10.1038/s41598-019-47852-8.
2
Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).不同血清钙、磷和甲状旁腺激素水平的透析患者的死亡风险:透析结局和实践模式研究(DOPPS)
Am J Kidney Dis. 2008 Sep;52(3):519-30. doi: 10.1053/j.ajkd.2008.03.020. Epub 2008 Jun 2.
3
International variations in serum PTH and calcium levels and their mortality associations in peritoneal dialysis patients: Results from PDOPPS.腹膜透析患者血清 PTH 和钙水平的国际差异及其与死亡率的关系:PDOPPS 研究结果。
Perit Dial Int. 2024 Jul;44(4):275-286. doi: 10.1177/08968608241235516. Epub 2024 Mar 19.
4
Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study.矿物质和骨代谢标志物的改善与血液透析患者的生存改善相关:COSMOS 研究。
Nephrol Dial Transplant. 2015 Sep;30(9):1542-51. doi: 10.1093/ndt/gfv099. Epub 2015 Apr 28.
5
Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study.在拉丁美洲的一个大型透析患者样本中,钙、磷、PTH 与死亡率的关系。CORES 研究。
Nephrol Dial Transplant. 2011 Jun;26(6):1938-47. doi: 10.1093/ndt/gfq304. Epub 2010 May 31.
6
Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.继发性甲状旁腺功能亢进症血液透析患者异常矿物质代谢与死亡:来自调整时间依赖性混杂因素的边缘结构模型的证据。
Am J Kidney Dis. 2014 Jun;63(6):979-87. doi: 10.1053/j.ajkd.2013.08.011. Epub 2013 Oct 8.
7
Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study.盐酸西那卡塞对日本透析治疗学会(JSDT)指南目标达成情况的影响:KRN1493研究的事后分析
Ther Apher Dial. 2008 Oct;12 Suppl 1:S44-9. doi: 10.1111/j.1744-9987.2008.00631.x.
8
Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients.对于长期透析患者,应首要且持续地控制血清磷和钙水平。
Ther Apher Dial. 2013 Apr;17(2):221-8. doi: 10.1111/1744-9987.12030.
9
Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy.对继发性甲状旁腺功能亢进的血液透析患者进行矿物质代谢的频繁监测:与治疗目标达成及治疗调整的相关性
Nephrol Dial Transplant. 2017 Mar 1;32(3):534-541. doi: 10.1093/ndt/gfw020.
10
Chronic kidney disease mineral bone disorder and health-related quality of life among incident end-stage renal-disease patients.初发终末期肾病患者的慢性肾脏病矿物质和骨异常与健康相关生活质量
J Ren Nutr. 2007 Sep;17(5):305-13. doi: 10.1053/j.jrn.2007.06.005.

引用本文的文献

1
The optimal range of serum intact parathyroid hormone for a lower risk of mortality in the incident hemodialysis patients.在新发生血液透析患者中,血清全段甲状旁腺激素的最佳范围可降低死亡率风险。
Ren Fail. 2021 Dec;43(1):599-605. doi: 10.1080/0886022X.2021.1903927.

本文引用的文献

1
Population attributable fraction.人群归因分数。
BMJ. 2018 Feb 22;360:k757. doi: 10.1136/bmj.k757.
2
Comparison of methods for estimating the attributable risk in the context of survival analysis.生存分析背景下可归因风险估计方法的比较
BMC Med Res Methodol. 2017 Jan 23;17(1):10. doi: 10.1186/s12874-016-0285-1.
3
PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism.西那卡塞对继发性甲状旁腺功能亢进血液透析患者有效性的甲状旁腺激素依赖性
Sci Rep. 2016 Apr 13;6:19612. doi: 10.1038/srep19612.
4
Concepts and pitfalls in measuring and interpreting attributable fractions, prevented fractions, and causation probabilities.归因分数、预防分数和因果概率的测量和解释中的概念和误区。
Ann Epidemiol. 2015 Mar;25(3):155-61. doi: 10.1016/j.annepidem.2014.11.005. Epub 2014 Nov 14.
5
Impact of cinacalcet introduction on MBD management: the MBD-5D study in Japan.西那卡塞引入对矿物质代谢紊乱管理的影响:日本的矿物质代谢紊乱-5D研究
Kidney Int Suppl (2011). 2013 Dec;3(5):436-441. doi: 10.1038/kisup.2013.91.
6
Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.继发性甲状旁腺功能亢进症血液透析患者异常矿物质代谢与死亡:来自调整时间依赖性混杂因素的边缘结构模型的证据。
Am J Kidney Dis. 2014 Jun;63(6):979-87. doi: 10.1053/j.ajkd.2013.08.011. Epub 2013 Oct 8.
7
Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder.慢性肾脏病-矿物质和骨异常管理的临床实践指南
Ther Apher Dial. 2013 Jun;17(3):247-88. doi: 10.1111/1744-9987.12058.
8
Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study.西那卡塞时代的处方模式和矿物质代谢异常:来自 MBD-5D 研究的结果。
Clin J Am Soc Nephrol. 2012 Sep;7(9):1473-80. doi: 10.2215/CJN.13081211. Epub 2012 Jul 19.
9
Mineral and bone disorders outcomes study for Japanese chronic kidney disease stage 5D patients: rationale and study design.日本慢性肾脏病5D期患者的矿物质与骨异常结局研究:原理与研究设计
Ther Apher Dial. 2011 Apr;15(2):169-75. doi: 10.1111/j.1744-9987.2010.00906.x. Epub 2011 Mar 2.
10
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).改善全球肾脏病预后组织(KDIGO)慢性肾脏病-矿物质和骨异常(CKD-MBD)诊断、评估、预防及治疗临床实践指南。
Kidney Int Suppl. 2009 Aug(113):S1-130. doi: 10.1038/ki.2009.188.